Suppr超能文献

机器人手术与腹腔镜手术治疗中低位直肠癌(REAL):一项多中心随机对照试验的短期结果

Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial.

作者信息

Feng Qingyang, Yuan Weitang, Li Taiyuan, Tang Bo, Jia Baoqing, Zhou Yanbing, Zhang Wei, Zhao Ren, Zhang Cheng, Cheng Longwei, Zhang Xiaoqiao, Liang Fei, He Guodong, Wei Ye, Xu Jianmin

机构信息

Department of Colorectal Surgery, Zhongshan Hospital Fudan University, Shanghai, China; Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China.

Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.

出版信息

Lancet Gastroenterol Hepatol. 2022 Nov;7(11):991-1004. doi: 10.1016/S2468-1253(22)00248-5. Epub 2022 Sep 8.

Abstract

BACKGROUND

Robotic surgery for rectal cancer is gaining popularity, but evidence on long-term oncological outcomes is scarce. We aimed to compare surgical quality and long-term oncological outcomes of robotic and conventional laparoscopic surgery in patients with middle and low rectal cancer. Here we report the short-term outcomes of this trial.

METHODS

This multicentre, randomised, controlled, superiority trial was done at 11 hospitals in eight provinces of China. Eligible patients were aged 18-80 years with middle (>5 to 10 cm from the anal verge) or low (≤5 cm from the anal verge) rectal adenocarcinoma, cT1-T3 N0-N1 or ycT1-T3 Nx, and no evidence of distant metastasis. Central randomisation was done by use of an online system and was stratified according to participating centre, sex, BMI, tumour location, and preoperative chemoradiotherapy. Patients were randomly assigned at a 1:1 ratio to receive robotic or conventional laparoscopic surgery. All surgical procedures complied with the principles of total mesorectal excision or partial mesorectal excision (for tumours located higher in the rectum). Lymph nodes at the origin of the inferior mesenteric artery were dissected. In the robotic group, the excision procedures and dissection of lymph nodes were done by use of robotic techniques. Neither investigators nor patients were masked to the treatment allocation but the assessment of pathological outcomes was masked to the treatment allocation. The primary endpoint was 3-year locoregional recurrence rate, but the data for this endpoint are not yet mature. Secondary short-term endpoints are reported in this article, including two key secondary endpoints: circumferential resection margin positivity and 30-day postoperative complications (Clavien-Dindo classification grade II or higher). The outcomes were analysed according in a modified intention-to-treat population (according to the original assigned groups and excluding patients who did not undergo surgery or no longer met inclusion criteria after randomisation). This trial was registered with ClinicalTrials.gov, number NCT02817126. Study recruitment has completed, and the follow-up is ongoing.

FINDINGS

Between July 17, 2016, and Dec 21, 2020, 1742 patients were assessed for eligibility. 502 patients were excluded, and 1240 patients were enrolled and randomly assigned to receive either robotic surgery (620 patients) or laparoscopic surgery (620 patients). 69 patients were excluded (34 in the robotic surgery group and 35 in the laparoscopic surgery group). 1171 patients were included in the modified intention-to-treat analysis (586 in the robotic group and 585 in the laparoscopic group). Six patients in the robotic surgery group received laparoscopic surgery and seven patients in the laparoscopic surgery group received robotic surgery. 22 (4·0%) of 547 patients in the robotic group had a positive circumferential resection margin as did 39 (7·2%) of 543 patients in the laparoscopic group (difference -3·2 percentage points [95% CI -6·0 to -0·4]; p=0·023). 95 (16·2%) of patients in the robotic group had at least one postoperative complication (Clavien-Dindo grade II or higher) within 30 days after surgery, as did 135 (23·1%) of 585 patients in the laparoscopic group (difference -6·9 percentage points [-11·4 to -2·3]; p=0·003). More patients in the robotic group had a macroscopic complete resection than in the laparoscopic group (559 [95·4%] of 586 patients vs 537 [91·8%] of 585 patients, difference 3·6 percentage points [0·8 to 6·5]). Patients in the robotic group had better postoperative gastrointestinal recovery, shorter postoperative hospital stay (median 7·0 days [IQR 7·0 to 11·0] vs 8·0 days [7·0 to 12·0], difference -1·0 [95% CI -1·0 to 0·0]; p=0·0001), fewer abdominoperineal resections (99 [16·9%] of 586 patients vs 133 [22·7%] of 585 patients, difference -5·8 percentage points [-10·4 to -1·3]), fewer conversions to open surgery (10 [1·7%] of 586 patients vs 23 [3·9%] of 585 patients, difference -2·2 percentage points [-4·3 to -0·4]; p=0·021), less estimated blood loss (median 40·0 mL [IQR 30·0 to 100·0] vs 50·0 mL [40·0 to 100·0], difference -10·0 [-20·0 to -10·0]; p<0·0001), and fewer intraoperative complications (32 [5·5%] of 586 patients vs 51 [8·7%] of 585 patients; difference -3·3 percentage points [-6·3 to -0·3]; p=0·030) than patients in the laparoscopic group.

INTERPRETATION

Secondary short-term outcomes suggest that for middle and low rectal cancer, robotic surgery resulted in better oncological quality of resection than conventional laparoscopic surgery, with less surgical trauma, and better postoperative recovery.

FUNDING

Shenkang Hospital Development Center, Shanghai Municipal Health Commission (Shanghai, China), and Zhongshan Hospital Fudan University (Shanghai, China).

摘要

背景

直肠癌的机器人手术越来越受欢迎,但关于长期肿瘤学结局的证据却很少。我们旨在比较机器人手术与传统腹腔镜手术治疗中低位直肠癌患者的手术质量和长期肿瘤学结局。在此,我们报告该试验的短期结局。

方法

本多中心、随机、对照、优效性试验在中国八个省份的11家医院进行。符合条件的患者年龄在18-80岁之间,患有中(距肛缘>5至10 cm)或低位(距肛缘≤5 cm)直肠腺癌,cT1-T3 N0-N1或ycT1-T3 Nx,且无远处转移证据。通过在线系统进行中心随机分组,并根据参与中心、性别、BMI、肿瘤位置和术前放化疗进行分层。患者按1:1的比例随机分配接受机器人手术或传统腹腔镜手术。所有手术均符合全直肠系膜切除或部分直肠系膜切除(针对直肠较高位置的肿瘤)原则。清扫肠系膜下动脉起始处的淋巴结。在机器人手术组中,切除程序和淋巴结清扫通过机器人技术完成。研究人员和患者均未对治疗分配进行盲法,但病理结局评估对治疗分配进行了盲法处理。主要终点是3年局部区域复发率,但该终点的数据尚未成熟。本文报告次要短期终点,包括两个关键次要终点:环周切缘阳性率和术后30天并发症(Clavien-Dindo分类II级或更高)。结局根据改良意向性治疗人群进行分析(根据最初分配的组,排除未接受手术或随机分组后不再符合纳入标准的患者)。本试验已在ClinicalTrials.gov注册,编号为NCT02817126。研究招募已完成,随访正在进行。

结果

2016年7月17日至2020年12月21日期间,对1742例患者进行了资格评估。排除502例患者,1240例患者入组并随机分配接受机器人手术(620例患者)或腹腔镜手术(620例患者)。排除69例患者(机器人手术组34例,腹腔镜手术组35例)。1171例患者纳入改良意向性治疗分析(机器人手术组586例,腹腔镜手术组585例)。机器人手术组有6例患者接受了腹腔镜手术,腹腔镜手术组有7例患者接受了机器人手术。机器人手术组547例患者中有22例(4.0%)环周切缘阳性,腹腔镜手术组543例患者中有39例(7.2%)环周切缘阳性(差异-3.2个百分点[95%CI -6.0至-0.4];p=0.023)。机器人手术组95例(16.2%)患者术后30天内至少发生1次并发症(Clavien-Dindo II级或更高),腹腔镜手术组585例患者中有135例(23.1%)发生并发症(差异-6.9个百分点[-11.4至-2.3];p=0.003)。机器人手术组肉眼完全切除的患者比腹腔镜手术组更多(586例患者中的559例[95.4%] vs 585例患者中的537例[91.8%],差异3.6个百分点[0.8至6.5])。机器人手术组患者术后胃肠道恢复更好,术后住院时间更短(中位数7.0天[IQR 7.0至11.0] vs 8.0天[7.0至12.0],差异-1.0[95%CI -1.0至0.0];p=0.0001),腹会阴联合切除术更少(586例患者中的99例[16.9%] vs 585例患者中的133例[22.7%],差异-5.8个百分点[-10.4至-1.3]),转为开放手术的更少(586例患者中的10例[1.7%] vs 585例患者中的23例[3.9%],差异-2.2个百分点[-4.3至-0.4];p=0.021),估计失血量更少(中位数40.0 mL[IQR 30.0至100.0] vs 50.0 mL[40.0至100.0],差异-10.0[-20.0至-10.0];p<0.0001),术中并发症更少(586例患者中的32例[5.5%] vs 585例患者中的51例[8.7%];差异-3.3个百分点[-6.3至-0.3];p=0.030)。

解读

次要短期结局表明,对于中低位直肠癌,机器人手术比传统腹腔镜手术的肿瘤切除质量更好,手术创伤更小,术后恢复更好。

资助

上海市卫生健康委员会申康医院发展中心(中国上海)和复旦大学附属中山医院(中国上海)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验